Glioma is the most common primary malignant brain tumor in adults and is difficult to cure with current treatment methods. Isocitrate dehydrogenase（ IDH） mutant gliomas exhibit molecular heterogeneity. The mutated IDH gene product D-2-Hydroxyglutarate（ D-2-HG） promotes DNA hypermethylation and immune suppression thereby driving tumor growth. In recent years， IDH inhibitors such as Ivosidenib and Vorasidenib have demonstrated the ability to reduce D-2-HG levels and induce cellular differentiation in preclinical models and early-phase clinical trials. The Phase Ⅲ INDIGO trial demonstrates that Vorasidenib significantly prolongs progression-free survival in patients with non-amplified grade 2 IDH mutant gliomas， and receives FDA approval in 2024. This paper provides a detailed overview of the progress of IDH inhibitors for gliomas treatment， highlighting their role as a well-tolerated therapeutic option that offers benefits for selected patient populations. Future research combining novel drugs and combination therapies may further expand its therapeutic potential.